{"entity":{"id":"etx-880","kind":"drug","name":"ETX-880","aka":[],"tldr":"ETX-880 is an experimental small molecule from Ensem Therapeutics, in preclinical development for MSI-high colorectal cancer, MSI-high gastric cancer and MSI-high endometrial cancer.","summary":"ETX-880 is a small molecule (oral, covalent) from Ensem Therapeutics. An oral, selective covalent inhibitor of Werner helicase (WRN), being developed for microsatellite instability-high cancers. Its furthest stage is preclinical development, for MSI-high colorectal cancer, MSI-high gastric cancer and MSI-high endometrial cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Pipeline page describes only in vitro and xenograft data; no ClinicalTrials.gov record for ETX-880. It has not been shown to work in people.","status":"preclinical","asOf":"2026-11-03","links":[{"label":"Ensem Therapeutics: ensemtx.com","url":"https://ensemtx.com/science/pipeline/"},{"label":"Ensem Therapeutics: ensemtx.com","url":"https://ensemtx.com/science/pipeline/"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["wrn"],"drugs":[],"companies":["ensem-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"ETX-880","modality":"Small molecule (oral, covalent)","mechanism":"An oral, selective covalent inhibitor of Werner helicase (WRN), being developed for microsatellite instability-high cancers.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/etx-880/","neighbours":{"target":[{"id":"wrn","kind":"target","name":"WRN helicase (MSI-high cancers)","route":"/targets/wrn/"}],"company":[{"id":"ensem-therapeutics","kind":"company","name":"Ensem Therapeutics","route":"/companies/ensem-therapeutics/"}]}}